ストックスクリーナーアプリを入手
7.67
3.37%
0.25
プレマーケット:
7.80
0.13
+1.69%
前日終値:
$7.42
開ける：
$7.45
24時間の取引高:
567.75K
Relative Volume:
0.66
時価総額：
$494.88M
収益：
$89.40M
当期純損益:
$-221.30M
株価収益率:
-2.3554
EPS:
-3.2564
ネットキャッシュフロー:
$-256.90M
1週間 パフォーマンス:
+9.89%
1か月 パフォーマンス:
-15.53%
6か月 パフォーマンス:
-34.56%
1年 パフォーマンス:
+2.54%
1日の値動き範囲:
$7.45
$7.86
1週間の範囲:
$6.97
$7.86
52週間の値動き範囲:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.67 | 483.26M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-06 | アップグレード | Citigroup | Neutral → Buy |
| 2025-10-15 | ダウングレード | Goldman | Neutral → Sell |
| 2025-09-24 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2025-06-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | ダウングレード | Truist | Buy → Hold |
| 2025-05-02 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-02 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-01 | 開始されました | Goldman | Buy |
| 2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 開始されました | Barclays | Overweight |
| 2022-06-21 | 開始されました | Jefferies | Hold |
| 2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2022-01-19 | 開始されました | Goldman | Buy |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-09 | 開始されました | BofA Securities | Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-21 | 開始されました | Truist | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Perform |
| 2019-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-25 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-25 | 開始されました | Wedbush | Outperform |
| 2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
| 2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-22 | 開始されました | Citigroup | Buy |
| 2018-10-22 | 開始されました | Goldman | Neutral |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Price-Driven Insight from (ARVN) for Rule-Based Strategy - Stock Traders Daily
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas sharpens pipeline focus after first PROTAC approval, eyes key trial data - MSN
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data - MarketBeat
Arvinas joins MJFF initiatives to advance LRRK2 research - BioWorld News
Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease - marketscreener.com
Arvinas, Inc. Joins The Michael J. Fox Foundation's LITE And PPMI Programs To Advance New Therapies Targeting LRRK2 For Parkinson's Disease - marketscreener.com
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI - GlobeNewswire
Arvinas joins Michael J. Fox effort to develop new Parkinson's therapies - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ARVN Reiterates by Stephens & Co. -- Price Target Maintained at $18 - GuruFocus
ARVN: First PROTAC degrader approved; pipeline prioritization and key milestones drive focus - TradingView
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development - TipRanks
ArvinasAnnounces Re-Prioritization Of Portfolio Following Strategic ReviewSEC Filing - TradingView
Arvinas reprioritizes pipeline, to complete ARV-806 Phase 1 data and seek out-license; cash runway into H2 2028 - TradingView
Arvinas (ARVN) refocuses ARV-806 strategy and projects cash runway into second half of 2028 - Stock Titan
(ARVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Full Transcript: Arvinas Q1 2026 Earnings Call - Benzinga
Monaco Asset Management SAM Has $833,000 Holdings in Arvinas, Inc. $ARVN - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - The Manila Times
Arvinas, Inc. to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 3, 2026 - Quiver Quantitative
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Arvinas Inc. (ARVN) Stabilizes Near Support Amid Biotech Sector CautionVolatility Skew - thelegaladvocate.com
Arvinas Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Arvinas Employees Give Back During Company-wide Impact Day - Sahm
Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - 富途牛牛
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts - Investing.com India
Earnings call transcript: Arvinas Inc. reports Q1 2026 earnings, stock reacts By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas staff spend a day cooking, cleaning and crafting for patients and kids - Stock Titan
These analysts increase their forecasts on Arvinas after Q1 results - MSN
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Arvinas Holding Company (ARVN) - The Globe and Mail
Analysts Just Published A Bright New Outlook For Arvinas, Inc.'s (NASDAQ:ARVN) - Sahm
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
HC Wainwright Comments on Arvinas' Q2 Earnings (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
Arvinas Inc (ARVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Teel Randy | President and CEO |
May 21 '26 |
Sale |
9.04 |
2,209 |
19,962 |
285,009 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):